• CervoMed completed enrollment in a Phase 2a study of neflamapimod in nonfluent variant primary progressive aphasia, a frontotemporal dementia subtype.
• Trial enrolled 25 participants on oral dosing for 24 weeks, testing 40 mg three times daily or 80 mg twice daily regimens.
• Interim biomarker data are slated for presentation at the CTAD conference in November 2026.
• First biomarker readout is expected in early Q4 2026; first clinical data are targeted for Q1 2027.
• Preclinical findings in Nature Neuroscience linked p38α inhibition to improved axonal transport in tau-mutation mouse models, supporting the program’s rationale.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Cervomed Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001437749-26-023200), on July 09, 2026, and is solely responsible for the information contained therein.